Altamira Therapeutics granted European patent for intranasal betahistine

Altamira Therapeutics has received an “Intention to Grant” notice from the European Patent Office for its patent application titled “Intranasal Composition Comprising Betahistine”. The application is a continuation of the previously granted European Patent 3474850 and upon issuance, is expected to remain valid until February 2038. Combined, these two patents will provide key intellectual property protection for the Company’s intranasal betahistine program in Europe. To date, the patent has been granted in around 50 countries worldwide, including key markets in North America and Europe. The allowed claims cover the composition of matter and methods of use for formulations of betahistine dihydrochloride for intranasal delivery.